Table 2.

Adverse events during two month follow-up

Adverse event	HLA-B*58:01 positive participants receiving alternative drug treatment (n=354)	HLA-B*58:01 negative participants receiving allopurinol (n=2173)	Total (n=2910)
Mild cutaneous events
Rash and itching	3*	94	97
Blisters	0	0	0
Oral ulcers	0	2	2
Rash, itching, oral ulcers, and fever	0	1	1
Rash, itching, and other adverse events	0	22	22
Severe cutaneous events
Drug reaction with eosinophilia and systemic symptoms	0	0	0
Urticaria	0	0	0
Stevens-Johnson syndrome or toxic epidermal necrolysis	0	0	0
Other adverse events†
Fever	0	1	1
Sore throat	0	2	2
Fatigue	0	5	5
Other	20	117	137

Data are no of participants having adverse events.

*All three participants took benzbromarone.

†Each participant may have had more than one adverse event. Adverse events with a low frequency are not listed.